R1T Demand Spurs Needham’s Bullish Outlook on Rivianby Mark Eisenberg 09.01.2024Investment firm Needham reiterates its bullish outlook on Rivian as R1T demand surges, setting a price target of $25.00 for ...
Argus remains optimistic on Boeing despite challengesby Mark Eisenberg 09.01.2024Argus maintains Buy rating on Boeing despite near-term challenges, citing its leading presence in the aerospace industry and potential for ...
Goldman Sachs Forecasts Russell 2000 Outlook for 2024by Terry Bingman 09.01.2024Goldman Sachs projects positive outlook for Russell 2000 small-cap stocks in 2024, expecting a return of 9% in the next ...
5 Stocks to Spice Up Your Portfolioby Mark Eisenberg 09.01.2024Chevron, Alibaba, Hertz Global, Madison Square Garden Sports, and Pepsico offer promising investment opportunities in various sectors with attractive valuations ...
Goldman Sachs Advises Utilizing Market Dips to Invest in Stocksby Mark Eisenberg 09.01.2024Goldman Sachs advises investors to take advantage of market pullbacks and buy stocks, highlighting the potential for higher returns in ...
Stocks Decline as Dow Opens Lower on Pre-market Mover Reportsby Mark Eisenberg 09.01.2024Tech stocks retreat as U.S. stock futures dip on inflation concerns, with investors closely watching economic data and central bank ...
Netflix Stock Falls as Citi Cuts Rating on ‘Lofty’ Expectationsby Terry Bingman 09.01.2024Netflix shares drop 2% as Citi cuts rating due to "lofty expectations" for 2024 and 2025. Concerns over revenue growth, ...
Navigating the 2024 Stock Market: Insights from Morgan Stanley’s Chiefby Terry Bingman 09.01.2024Morgan Stanley's Mike Wilson prepares investors for three growth scenarios in 2024, offering a stock market playbook for each and ...
Nasdaq Surges as Tech Stocks Propel Dow Jonesby Lilu Anderson 09.01.2024Tech giants rally as stocks bounce back, with Nvidia hitting a record high after unveiling new AI chips for personal ...
Calliditas Experiences Strong Q4 Growth, Looks to Expand in the Futureby Terry Bingman 09.01.2024Calliditas Therapeutics reports strong Q4 growth and sets sights on expansion, with TARPEYO sales surging 170% in 2023. CEO optimistic ...